HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat

Biochemical and Biophysical Research Communications

Volumn 370, Issue 1, 2008, Pages 22-26

  Cristillo, Anthony D ^a   Galmin, Lindsey ^a   Restrepo, Susana ^a   Hudacik, Lauren ^a   Suschak, John ^a   Lewis, Brad ^a   Draghia Akli, Ruxandra ^b   Aziz, Nazneen ^c   Weiss, Deborah ^a   Markham, Phillip ^a   Pal, Ranajit ^a  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b VGX Pharmaceuticals Inc   (United States)

^c Point Therapeutics   (United States)

Author keywords

Cellular immunity; Electroporation; HIV 1; Humoral immunity; Talabostat; Vaccine

Indexed keywords

DNA; GAMMA INTERFERON; GLYCOPROTEIN GP 120 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS 1 ENV VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 4; INTERLEUKIN 5; QS 21; RECOMBINANT ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; TALABOSTAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA BINDING; DRUG POTENCY; ELECTROPORATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; REACTION ANALYSIS; TH1 CELL; TH2 CELL;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; BORONIC ACIDS; CYTOKINES; DIPEPTIDES; DNA, VIRAL; ELECTROPORATION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 41849088021     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.145     Document Type: Article

References (35)

1. Cristillo A.D., Weiss D., Hudacik L., Restrepo S., Galmin L., Suschak J., Draghia-Akli R., Markham P., and Pal R. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem. Biophys. Res. Commun. 366 (2008) 29-35
2. Cristillo A.D., Lisziewicz J., He L., Lori F., Galmin L., Trocio J.N., Unangst T., Whitman L., Hudacik L., Bakare N., Whitney S., Restrepo S., Suschak J., Ferrari M.G., Chung H.K., Kalyanaraman V.S., Markham P., and Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366 (2007) 197-211
3. Cristillo A.D., Wang S., Caskey M.S., Unangst T., Hocker L., He L., Hudacik L., Whitney S., Keen T., Chou T.H., Shen S., Joshi S., Kalyanaraman V.S., Nair B., Markham P., Lu S., and Pal R. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346 (2006) 151-168
4. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., Hudacik L., Rose N., Mboudjeka I., Shen S., Wu-Chou T.H., Montefiori D., Mascola J., Markham P., and Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 (2006) 341-353
5. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., Liu Q., Whitney S., Keen T., Nair B.C., Kalyanaraman V.S., Markham P., and Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 (2006) 34-47
6. Otten G.R., Schaefer M., Doe B., Liu H., Srivastava I., Megede J., Kazzaz J., Lian Y., Singh M., Ugozzoli M., Montefiori D., Lewis M., Driver D.A., Dubensky T., Polo J.M., Donnelly J., O'Hagan D.T., Barnett S., and Ulmer J.B. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol. 79 (2005) 8189-8200
7. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., Shen S., Green S., Rothman A.L., Ennis F.A., Arthos J., Pal R., Markham P., and Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26 (2008) 1098-1110
8. Liu J., Hellerstein M., McDonnel M., Amara R.R., Wyatt L.S., Moss B., and Robinson H.L. Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. Vaccine 25 (2007) 2951-2958
9. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., Gorgone D.A., Beaudry K.R., Svehla K., Welcher B., Chakrabarti B.K., Huang Y., Yang Z.Y., Mascola J.R., Nabel G.J., and Letvin N.L. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79 (2005) 6516-6522
10. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., and Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113 (2004) 998-1007
11. Morel P.A., Falkner D., Plowey J., Larregina A.T., and Falo L.D. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22 (2004) 447-456
12. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., Garcia-Hand D., Abdullah R., Braun R., Montefiori D.C., Rosati M., Felber B.K., Pavlakis G.N., Mathiesen I., Israel Z.R., Eldridge J.H., and Egan M.A. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 81 (2007) 5257-5269
13. Patel J., Galey D., Jones J., Ray P., Woodward J.G., Nath A., and Mumper R.J. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine 24 (2006) 3564-3573
14. Lian Y., Srivastava I., Gomez-Roman V.R., Zur Megede J., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P.A., Otten G., Ulmer J.B., Donnelly J.J., Rabussay D., Montefiori D., van Rensburg E.J., and Barnett S.W. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79 (2005) 13338-13349
15. Alving C.R., Beck Z., Karasavva N., Matyas G.R., and Rao M. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. Mol. Membr. Biol. 23 (2006) 453-465
16. Kim M., Qiao Z., Yu J., Montefiori D., and Reinherz E.L. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 25 (2007) 5102-5114
17. Egan M.A., Chong S.Y., Hagen M., Megati S., Schadeck E.B., Piacente P., Ma B.J., Montefiori D.C., Haynes B.F., Israel Z.R., Eldridge J.H., and Staats H.F. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22 (2004) 3774-3788
18. Teleshova N., Kenney J., Van Nest G., Marshall J., Lifson J.D., Sivin I., Dufour J., Bohm R., Gettie A., and Robbiani M. Local and systemic effects of intranodally injected CpG-C immunostimulatory-oligodeoxyribonucleotides in macaques. J. Immunol. 177 (2006) 8531-8541
19. Guillon C., Mayol K., Terrat C., Compagnon C., Primard C., Charles M.H., Delair T., Munier S., and Verrier B. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25 (2007) 7491-7501
20. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., Keefer M.C., Kallas E.G., Corey L., Gorse G.J., Belshe R., Graham B.S., Spearman P.W., Schwartz D., Mulligan M.J., Goepfert P., Fast P., Berman P., Powell M., and Francis D. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19 (2001) 2080-2091
21. Sasaki S., Sumino K., Hamajima K., Fukushima J., Ishii N., Kawamoto S., Mohri H., Kensil C.R., and Okuda K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72 (1998) 4931-4939
22. Narra K., Mullins S.R., Lee H.O., Strzemkowski-Brun B., Magalong K., Christiansen V.J., McKee P.A., Egleston B., Cohen S.J., Weiner L.M., Meropol N.J., and Cheng J.D. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol. Ther. 6 (2007)
23. Cunningham C.C. Talabostat. Expert Opin. Invest. Drugs 16 (2007) 1459-1465
24. M. Jesson, P. McLean, G. Miller, S. Adams, J. Aubin, B. Jones, Mechanism of Action of Talabostat: A Dipeptidyl Peptidase Targeted Anti-Tumor Agent, American Association of Cancer Research (AACR) Annual Meeting, 2007.
25. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., Hudacik L., Rose N., Cristillo A., Mboudjeka I., Shen S., Wu-Chou T.H., Montefiori D., Mascola J., Lu S., and Markham P. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J. Med. Primatol. 34 (2005) 226-236
26. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., Tryniszewska E., Lewis M.G., VanCott T.C., Hirsch V., Woodward R., Gibson A., Grace M., Dobratz E., Markham P.D., Hel Z., Nacsa J., Klein M., Tartaglia J., and Franchini G. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76 (2002) 292-302
27. Pal R., Yu Q., Wang S., Kalyanaraman V.S., Nair B.C., Hudacik L., Whitney S., Keen T., Hung C.L., Hocker L., Kennedy J.S., Markham P.D., and Lu S. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 24 (2006) 1225-1234
28. Ronnberg B., Fekadu M., and Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 13 (1995) 1375-1382
29. Kensil C.R., Wu J.Y., and Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 6 (1995) 525-541
30. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J., and Marciani D. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12 (1994) 1275-1280
31. Carlson B.C., Jansson A.M., Larsson A., Bucht A., and Lorentzen J.C. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am. J. Pathol. 156 (2000) 2057-2065
32. Frey S., Poland G., Percell S., and Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21 (2003) 4234-4237
33. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., and Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24 (2004) 693-701
34. Ichikawa H.T., Williams L.P., and Segal B.M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169 (2002) 2781-2787
35. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4 (2004) 595-602